A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections

被引:4
|
作者
Dimopoulou, Dimitra [1 ]
Mantadakis, Elpis [2 ]
Koutserimpas, Christos [3 ]
Samonis, George [4 ,5 ]
机构
[1] Aghia Sophia Childrens Hosp, Dept Pediat 2, Athens 11527, Greece
[2] Univ Gen Hosp Alexandroupolis, Dept Pediat, Alexandroupolis 68100, Greece
[3] 251 Hellen AF Gen Hosp Athens, Dept Orthopaed & Traumatol, Athens 11525, Greece
[4] Univ Crete, Dept Med, Dept Radiol, Iraklion 71500, Greece
[5] Metropolitan Hosp, Dept Med Oncol 1, Attica 18547, Greece
来源
ANTIBIOTICS-BASEL | 2023年 / 12卷 / 10期
关键词
dalbavancin; bone and joint infections; osteomyelitis; septic arthritis; spondylodiscitis; diabetic foot infection; prosthetic joint infection; RESISTANT STAPHYLOCOCCUS-AUREUS; CLINICAL-PRACTICE GUIDELINES; ACUTE BACTERIAL SKIN; IN-VITRO ACTIVITY; ANTIBIOTIC-THERAPY; DISEASES SOCIETY; REAL-LIFE; SAFETY; PHARMACOKINETICS; VANCOMYCIN;
D O I
10.3390/antibiotics12101492
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bone and joint infections (BJI) require prolonged antimicrobial treatment, leading to lengthy hospitalizations, high costs, the risk of nosocomial infections, and the development of antimicrobial resistance. Dalbavancin is a novel semisynthetic lipoglycopeptide approved for the treatment of adults and children with acute bacterial skin and skin structure infections. This narrative review aims to summarize the characteristics of dalbavancin and the current scientific evidence regarding its clinical efficacy and safety in the treatment of BJI. A literature search until June 2023 was performed to identify all published research about the role of dalbavancin in the management of BJI. Due to its unique pharmacokinetics characterized by prolonged half-life, high bactericidal activity against most Gram-positive bacteria, a good safety profile, and high tissue penetration, dalbavancin can be a valuable alternative to the treatment of BJI. Clinical studies have shown its non-inferiority compared to conventional therapies in BJI, offering potent activity against key pathogens and an extended dosing interval that may shorten hospitalization. In conclusion, dalbavancin represents a promising treatment option for BJI with a favorable safety profile, but further research in both adults and particularly children, who are ideal candidates for long-acting antibiotics, is necessary to evaluate the role of dalbavancin in BJI.
引用
下载
收藏
页数:15
相关论文
共 50 条
  • [1] Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
    Buzon-Martin, Luis
    Zollner-Schwetz, Ines
    Tobudic, Selma
    Cercenado, Emilia
    Lora-Tamayo, Jaime
    ANTIBIOTICS-BASEL, 2021, 10 (06):
  • [2] Dalbavancin in Bone and Joint Infections: A Systematic Review
    Lovatti, Sofia
    Tiecco, Giorgio
    Mule, Alice
    Rossi, Luca
    Sforza, Anita
    Salvi, Martina
    Signorini, Liana
    Castelli, Francesco
    Quiros-Roldan, Eugenia
    PHARMACEUTICALS, 2023, 16 (07)
  • [3] Dalbavancin Use in Bone and Joint Infections
    Alderson, Liam P.
    Sanikommu, Srivani
    Mears, Simon C.
    Barnes, C. Lowry
    Stronach, Benjamin M.
    Stambough, Jeffrey B.
    Mcdonald, Jennifer
    Motes, Traci
    Bailey, Brett
    Dare, Ryan K.
    ARTHROPLASTY TODAY, 2024, 30
  • [4] Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections
    Morata, L.
    Cobo, J.
    Fernandez-Sampedro, M.
    Guisado Vasco, P.
    Ruano, E.
    Lora-Tamayo, J.
    Sanchez Somolinos, M.
    Gonzalez Ruano, P.
    Rico Nieto, A.
    Arnaiz, A.
    Estebanez Munoz, M.
    Jimenez-Mejias, M. E.
    Lozano Serrano, A. B.
    Munez, E.
    Rodriguez-Pardo, D.
    Argelich, R.
    Arroyo, A.
    Barbero, J. M.
    Cuadra, F.
    Del Arco, A.
    del Toro, M. D.
    Guio, L.
    Jimenez-Beatty, D.
    Lois, N.
    Martin, O.
    Martinez Alvarez, R. M.
    Martinez-Marcos, F. J.
    Porras, L.
    Ramirez, M.
    Vergas Garcia, J.
    Soriano, A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [5] Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments
    Lupia, Tommaso
    De Benedetto, Ilaria
    Bosio, Roberta
    Shbaklo, Nour
    De Rosa, Francesco Giuseppe
    Corcione, Silvia
    LIFE-BASEL, 2023, 13 (04):
  • [6] Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review
    Lora-Tamayo, Jaime
    Mancheno-Losa, Mikel
    Melendez-Carmona, Maria Angeles
    Hernandez-Jimenez, Pilar
    Benito, Natividad
    Murillo, Oscar
    ANTIBIOTICS-BASEL, 2024, 13 (04):
  • [7] Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review
    Matt, Morgan
    Duran, Clara
    Courjon, Johan
    Lotte, Romain
    Le Moing, Vincent
    Monnin, Boris
    Pavese, Patricia
    Chavanet, Pascal
    Khatchatourian, Lydie
    Tattevin, Pierre
    Cattoir, Vincent
    Lechiche, Catherine
    Illes, Gabriella
    Lacassin-Beller, Flore
    Senneville, Eric
    Dinh, Aurelien
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 25 : 341 - 345
  • [8] Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review
    Tsegka, Katerina G.
    Voulgaris, Georgios L.
    Kyriakidou, Margarita
    Kapaskelis, Anastasios
    Falagas, Matthew E.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (01) : 33 - 43
  • [9] Dalbavancin: A Review of Its Use in the Treatment of Gram-positive Infections
    Busse, Kristin H.
    Oltrogge, Kate M.
    Oxencis, Carolyn J.
    Peppard, William J.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 7 - 13
  • [10] Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review
    Telles, Joao Paulo
    Cieslinski, Juliette
    Tuon, Felipe Francisco
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2019, 23 (03): : 191 - 196